GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.

IF 2.2
Frontiers in clinical diabetes and healthcare Pub Date : 2025-08-27 eCollection Date: 2025-01-01 DOI:10.3389/fcdhc.2025.1579961
Nicolas Rea, Prakash V A K Ramdass
{"title":"GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.","authors":"Nicolas Rea, Prakash V A K Ramdass","doi":"10.3389/fcdhc.2025.1579961","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus (DM) is a global health challenge characterized by progressive beta cell dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising therapies, enhancing insulin secretion while potentially preserving beta cell mass by inhibiting apoptosis. However, concerns persist regarding long-term beta cell adaptation and functional exhaustion. This meta-analysis synthesizes preclinical evidence to evaluate the effects of GLP-1RAs on beta cell apoptosis in DM.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we systematically searched Scopus, PubMed, Embase, and Google Scholar for preclinical studies assessing GLP-1RAs effects on human beta cell apoptosis. Five studies met inclusion criteria for meta-analysis. Data were extracted on apoptotic rates, and risk of bias was assessed using the OHAT tool. A random-effects model calculated pooled mean differences (MDs) in apoptosis, with sensitivity analyses and funnel plots evaluating robustness and publication bias.</p><p><strong>Results: </strong>GLP-1RAs significantly reduced beta cell apoptosis (pooled MD: -0.10; 95% CI: -0.15 to -0.05, p = 0.0003), with high heterogeneity (I² = 100%). Sensitivity analyses confirmed consistency, with effect estimates ranging from -0.077 to -0.118 upon sequential study exclusion. Funnel plot and Egger's test (p = 0.80) indicated no significant publication bias, though limited study numbers constrain power.</p><p><strong>Conclusions: </strong>GLP-1RAs demonstrate a robust anti-apoptotic effect on pancreatic beta cells in preclinical models, supporting their role in preserving beta cell mass. However, extreme heterogeneity and unresolved questions about long-term functional exhaustion warrant cautious interpretation. Future research should prioritize longitudinal human studies to assess clinical relevance and optimize therapeutic strategies. Introduction.</p><p><strong>System review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024516313, identifier CRD42024516313.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1579961"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420244/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in clinical diabetes and healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fcdhc.2025.1579961","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Diabetes mellitus (DM) is a global health challenge characterized by progressive beta cell dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising therapies, enhancing insulin secretion while potentially preserving beta cell mass by inhibiting apoptosis. However, concerns persist regarding long-term beta cell adaptation and functional exhaustion. This meta-analysis synthesizes preclinical evidence to evaluate the effects of GLP-1RAs on beta cell apoptosis in DM.

Methods: Following PRISMA guidelines, we systematically searched Scopus, PubMed, Embase, and Google Scholar for preclinical studies assessing GLP-1RAs effects on human beta cell apoptosis. Five studies met inclusion criteria for meta-analysis. Data were extracted on apoptotic rates, and risk of bias was assessed using the OHAT tool. A random-effects model calculated pooled mean differences (MDs) in apoptosis, with sensitivity analyses and funnel plots evaluating robustness and publication bias.

Results: GLP-1RAs significantly reduced beta cell apoptosis (pooled MD: -0.10; 95% CI: -0.15 to -0.05, p = 0.0003), with high heterogeneity (I² = 100%). Sensitivity analyses confirmed consistency, with effect estimates ranging from -0.077 to -0.118 upon sequential study exclusion. Funnel plot and Egger's test (p = 0.80) indicated no significant publication bias, though limited study numbers constrain power.

Conclusions: GLP-1RAs demonstrate a robust anti-apoptotic effect on pancreatic beta cells in preclinical models, supporting their role in preserving beta cell mass. However, extreme heterogeneity and unresolved questions about long-term functional exhaustion warrant cautious interpretation. Future research should prioritize longitudinal human studies to assess clinical relevance and optimize therapeutic strategies. Introduction.

System review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024516313, identifier CRD42024516313.

Abstract Image

Abstract Image

Abstract Image

GLP-1受体激动剂与糖尿病胰腺β细胞凋亡:临床前研究的系统回顾和荟萃分析
糖尿病(DM)是一种以进行性β细胞功能障碍为特征的全球性健康挑战。胰高血糖素样肽-1受体激动剂(GLP-1RAs)已成为一种有前景的治疗方法,可通过抑制细胞凋亡来增强胰岛素分泌,同时潜在地保持β细胞质量。然而,对长期β细胞适应和功能衰竭的担忧仍然存在。本荟萃分析综合了GLP-1RAs对dm中β细胞凋亡影响的临床前证据。方法:遵循PRISMA指南,我们系统地检索了Scopus、PubMed、Embase和谷歌Scholar,以评估GLP-1RAs对人β细胞凋亡影响的临床前研究。5项研究符合meta分析的纳入标准。提取细胞凋亡率数据,并使用OHAT工具评估偏倚风险。随机效应模型计算细胞凋亡的汇总平均差异(MDs),通过敏感性分析和漏斗图评估稳健性和发表偏倚。结果:GLP-1RAs显著减少β细胞凋亡(合并MD: -0.10; 95% CI: -0.15 ~ -0.05, p = 0.0003),异质性高(I²= 100%)。敏感性分析证实了一致性,在序贯研究排除后,效应估计范围为-0.077至-0.118。漏斗图和Egger检验(p = 0.80)显示没有显著的发表偏倚,尽管有限的研究数量限制了有效性。结论:GLP-1RAs在临床前模型中对胰腺β细胞显示出强大的抗凋亡作用,支持其在保存β细胞质量中的作用。然而,关于长期功能衰竭的极端异质性和未解决的问题需要谨慎解释。未来的研究应优先考虑纵向人体研究,以评估临床相关性和优化治疗策略。介绍。系统评审注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD42024516313,标识符CRD42024516313。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信